EuroIntervention 2021;16:e1254-e1261 published online jacc November 2019 ■ published online e-edition February 2021

Ten-year trends, predictors and outcomes of mechanical circulatory support in percutaneous coronary intervention for acute myocardial infarction with cardiogenic shock

Saraschandra Vallabhajosyula*, MD; Abhiram Prasad, MD; Gurpreet S. Sandhu, MD, PhD; Malcolm R. Bell, MD; Rajiv Gulati, MD, PhD; Mackram F. Eleid, MD; Patricia J.M. Best, MD; Bernard J. Gersh, MBChB, DPhil; Mandeep Singh, MD; Amir Lerman, MD; David R. Holmes Jr, MD; Charanjit S. Rihal, MD; Gregory W. Barsness, MD

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA

A full list of study collaborators can be found in the Appendix paragraph.

This paper also includes supplementary data published online at: https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-19-00226

KEYWORDS

- ACS/NSTE-ACS
- cardiogenic shock
- IABP
- STEMI
- ventricular assist device

Abstract

Aims: There are limited data on the trends and outcomes of mechanical circulatory support (MCS)-assisted early percutaneous coronary intervention (PCI) in acute myocardial infarction with cardiogenic shock (AMI-CS). In this study, we sought to assess the use, temporal trends, and outcomes of percutaneous MCS-assisted early PCI in AMI-CS.

Methods and results: Using the National Inpatient Sample database from 2005-2014, a retrospective cohort of AMI-CS admissions receiving early PCI (hospital day zero) was identified. MCS use was defined as intra-aortic balloon pump (IABP), percutaneous left ventricular assist device (pLVAD) and extracorporeal membrane oxygenation (ECMO) support. Outcomes of interest included in-hospital mortality, resource utilisation, trends and predictors of MCS-assisted PCI. Of the 110,452 admissions, MCS assistance was used in 55%. IABP, pLVAD and ECMO were used in 94.8%, 4.2% and 1%, respectively. During 2009-2014, there was a decrease in MCS-assisted PCI due to a decrease in IABP, despite an increase in pLVAD and ECMO. Younger age, male sex, lower comorbidity, and cardiac arrest independently predicted MCS use. MCS-assisted PCI was predictive of higher in-hospital mortality (31% vs 26%, adjusted odds ratio 1.23 [1.19-1.27]; p<0.001) and greater resource utilisation. IABP-assisted PCI had lower in-hospital mortality and lesser resource utilisation compared to pLVAD/ECMO.

Conclusions: MCS-assisted PCI identified a sicker AMI-CS cohort. There was a decrease in IABP and an increase in pLVAD/ECMO.

**Corresponding author: Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. E-mail: Vallabhajosyula.Saraschandra@mayo.edu*

SUBMITTED ON 28/02/2019 - REVISION RECEIVED ON 1st 08/08/2019 / 2nd 13/11/2019 - ACCEPTED ON 14/11/2019

DOI: 10.4244/EIJ-D-19-00226

Abbreviations

AMI	acute myocardial infarction
CI	confidence interval
CS	cardiogenic shock
ECMO	extracorporeal membrane oxygenation
HCUP-NIS	Healthcare Cost and Utilization Project-National Inpatient Sample
IABP	intra-aortic balloon pump
ICD-9CM	International Classification of Diseases-9 Clinical Modification
MCS	mechanical circulatory support
NSTEMI	non-ST-elevation myocardial infarction
OR	odds ratio
PCI	percutaneous coronary intervention
pLVAD	percutaneous left ventricular assist device
STEMI	ST-elevation myocardial infarction

Introduction

Acute myocardial infarction (AMI) continues to be a leading cause of cardiovascular death and is associated with 30-45% mortality in patients with concomitant cardiogenic shock (CS)[1-5]. Contemporary guidelines from United States societies recommend emergent revascularisation in all ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) patients with haemodynamic instability[6,7]. Patients with AMI-CS are at a high risk for decompensation due to pre-existing left ventricular dysfunction, higher comorbidity, concomitant multivessel disease and complex coronary anatomy[8]. Percutaneous left ventricular assist devices (pLVAD) and extracorporeal membrane oxygenation (ECMO) are increasingly being used in the management of CS along with a decrease in intra-aortic balloon pump (IABP) use[5,9-11]. There are limited contemporary data on the concomitant use of MCS to support early PCI in AMI-CS[12-14]. Using a 10-year nationally representative database, we sought to assess the use, temporal trends and outcomes of percutaneous MCS-assisted early PCI (hospital day zero) in AMI-CS.

Editorial, see page 1211

Methods and material

STUDY POPULATION, VARIABLES AND OUTCOMES

The Healthcare Quality and Utilization Project – National Inpatient Sample (HCUP-NIS) is the largest all-payer database of hospital inpatient stays, containing discharge data from a 20% stratified sample of community hospitals in the USA[15]. Similar to prior literature, using previously validated methodology, a retrospective study cohort of admissions with AMI-CS was identified from the HCUP-NIS database from January 2005 to December 2014[1-4,9,10]. Because the International Classification of Diseases 9 Clinical Modification (ICD-9CM) codes were redefined in 2005 to distinguish between permanent MCS and short-term non-implantable devices, admissions before 2005 were excluded from this study[9,10]. AMI in the primary procedure field were identified using ICD-9CM codes 410.1x-410.9x and a secondary diagnosis of CS by ICD-9CM 785.51[16]. Early PCI was defined as PCI performed on hospital day zero. We used the procedure day for IABP (ICD-9CM 37.61), pLVAD (ICD-9CM 37.68), and ECMO (ICD-9CM 39.65) to time the MCS placement on the same day as the PCI procedure[14]. Demographic characteristics, hospital characteristics, primary payer, acute organ failure, organ support and comorbidities (Deyo's modification of the Charlson Comorbidity Index) were abstracted **(Supplementary Table 1)**[1-4,17-22].

The primary outcome was the frequency, utilisation trends, and predictors for MCS use in early PCI in AMI-CS. Secondary outcomes included in-hospital mortality, length of stay, and discharge disposition in admissions with AMI-CS that received MCS-assisted PCI in comparison to those that received early PCI alone.

STATISTICAL ANALYSIS

As recommended by HCUP-NIS, survey procedures using discharge weights provided with the HCUP-NIS database were used to generate national estimates. Using the trend weights provided by the HCUP-NIS, samples from 2000-2011 were re-weighted to adjust for the 2012 HCUP-NIS re-design[23]. Using trend weights available on the HCUP-NIS database, samples from 2000-2011 were retroactively re-weighted. The new sampling strategy is expected to result in more precise estimates than the previous HCUP-NIS design by reducing sampling error[15]. All analyses were conducted accounting for clustering of admissions within a hospital (HOSP_NIS), weighting (DISCWT), and stratification (NIS_STRATUM) of the NIS consistent with prior data[24]. Chi-square and t-tests were used to compare categorical and continuous variables, respectively. Univariable analysis for trends and outcomes was performed. These were represented as odds ratio (OR) with 95% confidence interval (CI). Multivariable logistic regression analysis was performed for predictors of MCS use and in-hospital mortality. To confirm the results of the primary findings, subgroup analyses stratifying admissions by age, sex, race, type of AMI and presence of cardiac arrest were performed. In the MCS-assisted PCI cohort, *a priori* comparison of pLVAD and ECMO to IABP was performed. A two-tailed $p<0.05$ was considered statistically significant. All statistical analyses were performed using SPSS, Version 25.0 (IBM Corp., Armonk, NY, USA).

Results

There were an estimated 6,111,445 admissions for AMI between January 2005 and December 2014, of which early PCI (hospital day 0) for AMI-CS was performed in 110,452 admissions **(Figure 1A, Figure 1B)**. There was an overall increase in the total admissions for AMI-CS receiving early PCI in this study period, with 86.5% encompassing ST-elevation AMI-CS. Percutaneous MCS was used concomitantly with early PCI in 60,487 (54.8%) admissions, with the IABP in 57,337 (94.8%), pLVAD in 2,568 (4.2%) and ECMO in 582 (1.0%). IABP remained the predominant MCS device of choice, though there was a decrease in use from 2009 **(Figure 2A, Figure 2B)**. MCS-assisted PCI was performed more frequently in admissions that were younger, male and



Figure 1. *Study cohort. A) Consort diagram for selection of study cohort from all AMI admissions in the USA. B) 10-year temporal trends of total admissions with AMI-CS receiving early PCI (hospital day zero).*

non-white, and with lower comorbidity **(Table 1, Supplementary Table 2)**. The MCS-assisted PCI cohort had higher rates of cardiac arrest (26% vs 21%; p<0.001) and respiratory failure requiring endotracheal intubation (40% vs 28%; p<0.001) on admission. During the hospital course, the MCS-assisted PCI cohort developed higher rates of non-cardiac organ failure **(Supplementary Table 2)**. Temporal trends of MCS-assisted PCI stratified by patient and hospital characteristics are presented in **Supplementary Figure 1** and **Supplementary Figure 2**. Multivariable logistic regression analysis for predictors of MCS use for early PCI is presented in **Table 2**. Younger age, male sex, non-white race, lower comorbidity, non-Medicare insurance, concomitant cardiac arrest, endotracheal intubation, and admission to a medium- or large-sized hospital were independent predictors of MCS use for early PCI.

The unadjusted in-hospital mortality (31.0% vs 25.8%, OR 1.29, 95% CI: 1.26-1.33; p<0.001) was significantly higher in the cohort with MCS-assisted PCI (**Figure 3A**, **Figure 3B** for temporal trends). Use of MCS assistance for early PCI was independently predictive of higher in-hospital mortality (OR 1.23, 95% CI: 1.19-1.27; p<0.001) **(Supplementary Table 3)**. Other significant predictors of in-hospital mortality included older age, earlier year of admission, and acute non-cardiac organ failure. These results remained consistent when admissions were stratified by age, sex, race, type of AMI-CS and presence of cardiac arrest **(Figure 4)**. The MCS-assisted PCI cohort had longer length of stay and fewer discharges to home **(Table 3)**.

In the MCS-assisted PCI cohort, pLVAD and ECMO were used more commonly in AMI-CS with concomitant cardiac arrest and respiratory failure requiring endotracheal intubation compared to IABP **(Supplementary Table 4)**. Unadjusted in-hospital mortality was higher in the groups with pLVAD (49% vs 30%, OR 2.25, 95% CI: 2.08-2.43; p<0.001) and ECMO (54% vs 30%, OR 2.75, 95% CI: 2.33-3.24; p<0.001) compared to the IABP cohort. In a multivariable analysis incorporating demographics, hospital characteristics, comorbidity, acute organ failure and organ support, use of pLVAD (OR 2.21, 95% CI: 2.01-2.43; p<0.001) and ECMO



Figure 2. *Temporal trends in the use of MCS assistance for early PCI in AMI-CS. A) 10-year temporal trends demonstrating the proportion of cases receiving MCS assistance for early PCI in AMI-CS. B) 10-year temporal trends of individual MCS devices for PCI assistance in AMI-CS; all p<0.001 for trend (picture-in-picture is used to provide greater magnification of pLVAD and ECMO use).*

Table 1. Baseline characteristics of cohorts with and without MCS-assisted early PCI.

Characteristic		MCS-assisted PCI (N=60,487)	PCI without MCS (N=49,965)	*p*-value
AMI type	ST-elevation	87.3	85.6	<0.001
	Non-ST-elevation	12.7	14.4	<0.001
Age, years		64.8±12.7	66.9±13.1	<0.001
Female sex		31.0	40.1	<0.001
Race	White	67.9	70.9	<0.001
	Black	6.1	5.5	
	Others*	26.0	23.6	
Inter-hospital transfers		18.3	18.2	0.87
Primary payer	Medicare	47.9	54.8	<0.001
	Medicaid	8.4	7.0	
	Others**	43.8	38.1	
Hospital region	Northeast	20.8	14.6	<0.001
	Midwest	20.1	22.4	
	South	38.6	40.1	
	West	20.6	22.9	
Charlson Comorbidity Index	0-3	36.6	32.2	<0.001
	4-6	49.6	49.3	
	≥7	13.9	18.5	
Comorbidities	Hyperlipidaemia	42.0	45.7	<0.001
	Chronic kidney disease	11.5	13.8	<0.001
	Heart failure	48.0	42.3	<0.001

Represented as percentage or mean±standard deviation. *Hispanic, Asian, Native American, Others, Missing. **Private, Uninsured, No charge, Others.

(OR 3.09, 95% CI: 2.53-3.76; p<0.001) for PCI assistance were associated with higher in-hospital mortality. Compared to pLVAD and ECMO, admissions with IABP were discharged home more frequently (42% vs 11% vs 53%; p<0.001) and with a shorter length of stay (9.6±10.4 vs 16.7±22.5 vs 9.5±9.4 days; p<0.001).



Figure 4. *Multivariate predictors of in-hospital mortality in AMI-CS receiving MCS-assisted early PCI compared to those without MCS-assisted PCI. Multivariable adjusted odds ratios (95% confidence intervals)* for in-hospital mortality in the admissions receiving early PCI stratified by age, sex, race, type of AMI-CS and presence of cardiac arrest; all p<0.001. *Adjusted for age, sex, race, year of admission, primary payer, socio-economic status, hospital location/teaching status, hospital bed size, hospital region, comorbidity, type of AMI, acute organ failure, cardiac arrest, invasive haemodynamic monitoring, mechanical ventilation and haemodialysis.*

Discussion

In this nationally representative study of 110,452 patient admissions with AMI-CS who underwent early PCI (day of admission), we noted MCS use in 55% of the admissions. The IABP remained the most commonly used MCS device with a decrease in utilisation between 2009 (98.5%) and 2014 (86.6%). Between 2009 and 2014, though there was a concomitant increase in the use of pLVAD (1.1% to 11.3%) and ECMO (0.4% to 2.1%), the overall trend for MCS-assisted PCI showed a decrease from 2009 (59.1% to 49.7%). Younger age, male sex, non-white race, lower comorbidity, concomitant cardiac arrest and endotracheal intubation



Figure 3. *Temporal trends of in-hospital mortality in AMI-CS receiving early PCI. A) Unadjusted temporal trends of in-hospital mortality in AMI-CS receiving early PCI stratified by MCS use (p<0.001 for trend over time). B) Adjusted temporal trends for in-hospital mortality in AMI-CS receiving early PCI stratified by MCS use with 2000 as referent year; adjusted for age, sex, race, primary payer status, socio-economic stratum, hospital characteristics, comorbidities, AMI type, acute organ failure, cardiac arrest, invasive haemodynamic monitoring, intubation on admission, and haemodialysis use (p<0.001).*

Table 2. Multivariable regression analysis for predictors of MCS-assisted early PCI.

Total cohort (N=110,452)		Odds ratio	95% confidence interval		*p*-value
			Lower limit	Upper limit	
Age groups, years	19-49	Reference category			
	50-59	0.98	0.94	1.03	0.52
	60-69	0.92	0.87	0.97	0.004
	70-79	0.90	0.84	0.96	0.001
	≥80	0.76	0.71	0.82	<0.001
Female sex		0.71	0.69	0.73	<0.001
Race	White	Reference category			
	Black	1.18	1.11	1.24	<0.001
	Hispanic	1.34	1.27	1.41	<0.001
	Asian	1.15	1.07	1.24	<0.001
	Native American	0.99	0.82	1.19	0.90
	Others	1.20	1.13	1.29	<0.001
Primary payer	Medicare	Reference category			
	Medicaid	1.11	1.05	1.18	<0.001
	Private	1.08	1.04	1.13	<0.001
	Uninsured	1.09	1.03	1.15	0.005
	No charge	0.84	0.71	1.00	0.05
	Others	1.05	0.97	1.14	0.24
Quartile of median household income for zip code	0-25th	Reference category			
	26th-50th	1.00	0.97	1.04	0.87
	51st-75th	1.01	0.98	1.05	0.50
	76th-100th	1.04	0.99	1.08	0.09
Hospital teaching status and location	Rural	Reference category			
	Urban non-teaching	0.97	0.91	1.03	0.38
	Urban teaching	0.99	0.94	1.06	0.87
Hospital bed size	Small	Reference category			
	Medium	1.13	1.07	1.20	<0.001
	Large	1.26	1.20	1.33	<0.001
Hospital region	Northeast	Reference category			
	Midwest	0.61	0.58	0.64	<0.001
	South	0.67	0.64	0.70	<0.001
	West	0.60	0.58	0.63	<0.001
Charlson Comorbidity Index	0-3	Reference category			
	4-6	1.05	1.01	1.09	0.01
	≥7	0.86	0.82	0.91	<0.001
Cardiac arrest		1.14	1.11	1.18	<0.001
Intubated at admission (day 0)		1.72	1.67	1.77	<0.001

were significant predictors of MCS use. The MCS-assisted PCI cohort was sicker and had higher in-hospital mortality and greater resource utilisation compared to AMI-CS patients receiving early PCI without MCS use. Despite the higher uptake in pLVAD and ECMO devices to support PCI, there has not been a significant decrease in in-hospital mortality in AMI-CS admissions.

Table 3. Clinical outcomes of cohorts with and without MCS-assisted early PCI.

Outcomes		MCS-assisted PCI (N=60,487)	PCI without MCS (N=49,965)	*p*-value
In-hospital mortality		31.0	25.8	<0.001
Length of stay (days)		9.6±9.7	8.1±9.3	<0.001
Discharge disposition	Home	52.5	59.2	<0.001
	Transferred to other hospitals	10.1	5.6	
	Skilled nursing facility	21.6	21.2	
	Home with home health care	15.1	13.2	
	Against medical advice	0.5	0.6	

Represented as percentage or mean±standard deviation.

MECHANICAL CIRCULATORY SUPPORT IN AMI-CS

Prior analyses on AMI-CS and MCS using large databases have focused on unselected MCS use, unselected CS patients and MCS-assisted PCI in all-comers[14,25,26]. In contrast to these studies, our data address a very specific population of STEMI and NSTEMI patients with CS who were treated with emergent PCI within the first 24 hours. These patients are typically sicker than unselected AMI-CS patients and therefore may benefit the most from MCS implantation. As noted in this study and by other groups, there has been a steady increase in the use of percutaneous MCS devices in the catheterisation laboratory for the management of AMI-CS[5,9,10,14,27]. The IABP has been the traditional device of choice in AMI-CS, with more recent data demonstrating an increase in the use of pLVAD and ECMO[27]. In AMI-CS patients, compared to the IABP, the Impella® device (Abiomed, Danvers, MA, USA) has not shown a significant outcome benefit despite improved haemodynamic stabilisation[28]. Contrary to these studies, we noted higher in-hospital mortality in the pLVAD and ECMO cohorts as compared to the IABP cohort. Potential explanations for this higher mortality include (i) higher acuity of illness in the pLVAD cohort, that could not be measured holistically due to lack of physiological data, (ii) confounding by indication in this real-world population and (iii) variability in the use of these devices since the study period was before societal guidelines on percutaneous MCS[13], and (iv) higher number of post-cardiac arrest patients in the MCS group who may not benefit from MCS if they have catastrophic neurologic injury. These results are consistent with prior retrospective analyses in patients with unselected CS that have demonstrated higher mortality in patients with pLVAD use and are worthy of further study in carefully designed prospective trials[5,9,10,14,27]. The widespread adoption of these devices may be associated with "indication creep", wherein these devices are used in younger and less sick patients who are least likely to benefit from them. These patients may benefit from the adoption of a multidisciplinary team approach for careful patient, procedure and treatment selection[4,5,17,29-31]. Further strategies targeting aspects such as multidisciplinary care, standardised protocols, and prevention of metabolic injury and complications remain priorities in this field[4,17,29,32].

TRENDS IN THE USE OF MECHANICAL CIRCULATORY SUPPORT

Traditionally, the IABP has been used for left ventricular support during PCI in AMI-CS; however, there has been a trend towards decreasing use in recent years[5,9,10,14,27]. Despite the lack of a demonstrable mortality benefit from the IABP in AMI-CS, >85% of the population in this study received an IABP for MCS-assisted PCI[11]. Around the year 2009, there was an increase in use of pLVAD and ECMO, with a significant increase around 2012. This could be postulated to be due to the influence of two important studies, i.e., the IABP-SHOCK (Intraaortic Balloon Pump in Cardiogenic Shock) and PROTECT II (Prospective, multicenter, randomized controlled trial of the Impella Recover LP 2.5 system versus IABP in patients undergoing non-emergent high risk PCI) trials that were published in 2012[11,12]. Furthermore, we demonstrated female sex and non-white race to be associated with lower use of MCS-assisted early PCI and that these had higher in-hospital mortality. These sex and race disparities have been noted in prior studies in a different population of acute cardiac care patients and are worthy of careful assessment in AMI-CS patients[17]. Hospital-level disparities exist in the outcomes of AMI-CS patients receiving MCS[1]. Prior work from our group has shown larger hospitals to have lower in-hospital mortality in AMI-CS; however, the mortality is higher in those receiving MCS[1,9,10]. This can be postulated to be due to the higher acuity of this population not fully accounted for by various regression analyses. Prior literature has shown a volume-outcome relationship in unselected CS patients that has resulted in an advocacy for multidisciplinary care in specialised shock centres[33]. Due to the sampling design changes to the HCUP-NIS database in 2012, this study was unable to assess the relationship of hospital volume with outcomes in these patients. However, using hospital location and size as a surrogate for case volume and presence of multidisciplinary teams, we were unable to demonstrate differences in in-hospital mortality.

Limitations

This study has several limitations, some of which are inherent to the analysis of a large administrative database. The definition of CS was based on discharge diagnoses and not haemodynamic parameters. However, prior validation studies have shown high specificity (99%) and negative predictive value (98%) for this definition[34]. Furthermore, the definitions used for AMI and organ failure have been validated previously, which may decrease the inherent issues associated with the use of administrative codes[4,16]. Since further granularity in timing beyond day of procedure is unavailable, and AMI-CS evolves dynamically during the first 24 hours, it is possible that this study included patients who received MCS for cardiac arrest, worsening CS or post-PCI complications independent of the need for supporting the index PCI. Information on vasoactive medication use and dosing, laboratory parameters (peak serum lactate, serum creatinine, haemoglobin, bicarbonate, acid-base balance, etc.), left ventricular function, and haemodynamic variables known to influence outcomes in this population, were unavailable in the HCUP-NIS database. Therefore, the multivariable analyses performed in this study are unable to account for these important parameters. The timing and duration of CS, which are known to influence mortality, could not be reliably measured from this database[8]. However, by restricting our outcomes to early PCI, we are optimistic that most patients in either cohort presented with CS at admission. Angiographic data, such as target vessel for PCI, classification and the presence of multivessel disease with/without chronic total occlusions, that may significantly influence outcomes, were not available in this database. Despite these limitations, this study addresses an important knowledge gap, highlighting the national use of MCS to assist PCI in AMI-CS.

Conclusions

In this study of 110,452 admissions with AMI-CS that underwent early PCI, we noted that more than half the population received concomitant MCS. Though the IABP remains the most commonly used device, there has been a steady increase in the use of pLVAD and ECMO in recent years. The use of MCS identified a sicker cohort of AMI-CS patients. The cohorts with pLVAD and ECMO use had higher in-hospital mortality and resource utilisation compared to the IABP cohort, highlighting the need for further careful study in dedicated prospective studies.

Impact on daily practice

Mechanical circulatory support-assisted percutaneous coronary intervention in acute myocardial infarction with cardiogenic shock identified a sicker population with higher in-hospital mortality. Careful selection of patients and procedures is needed to improve outcomes in this critically ill population.

Appendix. Study collaborators

John F. Bresnahan, MD; *Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA*. Guy S. Reeder, MD; *Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA*.

Conflict of interest statement

The authors/study collaborators have no conflicts of interest to declare.

References

1. Vallabhajosyula S, Dunlay SM, Barsness GW, Rihal CS, Holmes DR Jr, Prasad A. Hospital-Level Disparities in the Outcomes of Acute Myocardial Infarction With Cardiogenic Shock. *Am J Cardiol.* 2019;124:491-8.

2. Vallabhajosyula S, Dunlay SM, Kashani K, Vallabhajosyula S, Vallabhajosyula S, Sundaragiri PR, Jaffe AS, Barsness GW. Temporal trends and outcomes of prolonged invasive mechanical ventilation and tracheostomy use in acute myocardial infarction with cardiogenic shock in the United States. *Int J Cardiol.* 2019;285:6-10.

3. Vallabhajosyula S, Dunlay SM, Murphree DH Jr, Barsness GW, Sandhu GS, Lerman A, Prasad A. Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction: An 8-Year National Perspective on Clinical Characteristics, Management, and Outcomes. *JACC Heart Fail.* 2019;7:469-76.

4. Vallabhajosyula S, Dunlay SM, Prasad A, Kashani K, Sakhuja A, Gersh BJ, Jaffe AS, Holmes DR Jr, Barsness GW. Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock. *J Am Coll Cardiol.* 2019;73:1781-91.

5. Vallabhajosyula S, O'Horo JC, Antharam P, Ananthaneni S, Vallabhajosyula S, Stulak JM, Eleid MF, Dunlay SM, Gersh BJ, Rihal CS, Barsness GW. Concomitant Intra-Aortic Balloon Pump Use in Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation. *Circ Cardiovasc Interv.* 2018;11:e006930.

6. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2013;61:e78-140.

7. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014;64:e139-228.

8. Brennan JM, Curtis JP, Dai D, Fitzgerald S, Khandelwal AK, Spertus JA, Rao SV, Singh M, Shaw RE, Ho KK, Krone RJ, Weintraub WS, Weaver WD, Peterson ED; National Cardiovascular Data Registry. Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention: results from 1,208,137 procedures in the NCDR (National Cardiovascular Data Registry). *JACC Cardiovasc Interv.* 2013;6:790-9.

9. Vallabhajosyula S, Arora S, Kumar V, Shantha GPS, Jentzer JC, Stulak JM, Gersh BJ, Gulati R, Rihal CS, Prasad A, Deshmukh AJ. Temporary Mechanical Circulatory Support for Refractory Cardiogenic Shock Prior To Left Ventricular Assist Device Surgery. *J Am Heart Assoc.* 2018;7:e010193.

10. Vallabhajosyula S, Arora S, Sakhuja A, Lahewala S, Kumar V, Shantha GPS, Egbe AC, Stulak JM, Gersh BJ, Gulati R, Rihal CS, Prasad A, Deshmukh AJ. Trends, Predictors, and Outcomes of Temporary Mechanical Circulatory Support for Postcardiac Surgery Cardiogenic Shock. *Am J Cardiol.* 2019;123:489-97.

11. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Böhm M, Ebelt H, Schneider S, Schuler G, Werdan K; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med.* 2012;367:1287-96.

12. O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, Palacios I, Maini B, Mulukutla S, Dzavik V, Popma J, Douglas PS, Ohman M. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. *Circulation.* 2012;126:1717-27.

13. Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, Kern M, Garratt KN, Goldstein JA, Dimas V, Tu T; Society for Cardiovascular Angiography and Interventions (SCAI); Heart Failure Society of America (HFSA); Society of Thoracic Surgeons (STS); American Heart Association (AHA), and American College of Cardiology (ACC). 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. *J Am Coll Cardiol.* 2015;65:e7-26.

14. Khera R, Cram P, Vaughan-Sarrazin M, Horwitz PA, Girotra S. Use of Mechanical Circulatory Support in Percutaneous Coronary Intervention in the United States. *Am J Cardiol.* 2016;117:10-6.

15. Introduction to the HCUP Nationwide Inpatient Sample 2009. http://www.hcup-us.ahrq.gov/db/nation/nis/NIS_2009_INTRODUCTION.pdf. Accessed 18 January 2015.

16. Coloma PM, Valkhoff VE, Mazzaglia G, Nielsson MS, Pedersen L, Molokhia M, Mosseveld M, Morabito P, Schuemie MJ, van der Lei J, Sturkenboom M, Trifiro G; EU-ADR Consortium. Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. *BMJ Open.* 2013;3:e002862.

17. Vallabhajosyula S, Prasad A, Dunlay SM, Murphree DH Jr, Ingram C, Mueller PS, Gersh BJ, Holmes DR Jr, Barsness GW. Utilization of Palliative Care for Cardiogenic Shock Complicating Acute Myocardial Infarction: A 15-Year National Perspective on Trends, Disparities, Predictors, and Outcomes. *J Am Heart Assoc.* 2019;8:e011954.

18. Vallabhajosyula S, Ya'Qoub L, Dunlay SM, Vallabhajosyula S, Vallabhajosyula S, Sundaragiri PR, Jaffe AS, Gersh BJ, Kashani K. Sex disparities in acute kidney injury complicating acute myocardial infarction with cardiogenic shock. *ESC Heart Fail.* 2019;6:874-7.

19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol.* 1992;45:613-9.

20. Vallabhajosyula S, Dunlay SM, Barsness GW, Vallabhajosyula S, Vallabhajosyula S, Sundaragiri PR, Gersh BJ, Jaffe AS, Kashani K. Temporal trends, predictors, and outcomes of acute kidney injury and hemodialysis use in acute myocardial infarction-related cardiogenic shock. *PLoS One.* 2019;14:e0222894.

21. Vallabhajosyula S, Kashani K, Dunlay SM, Vallabhajosyula S, Vallabhajosyula S, Sundaragiri PR, Gersh BJ, Jaffe AS, Barsness GW. Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000-2014. *Ann Intensive Care.* 2019;9:96.

22. Vallabhajosyula S, Prasad A, Gulati R, Barsness GW. Contemporary prevalence, trends, and outcomes of coronary chronic total occlusions in acute myocardial infarction with cardiogenic shock. *Int J Cardiol Heart Vasc.* 2019;24:100414.

23. Khera R, Krumholz HM. With Great Power Comes Great Responsibility: Big Data Research From the National Inpatient Sample. *Circ Cardiovasc Qual Outcomes.* 2017;10:e003846.

24. Patel N, Gupta A, Doshi R, Kalra R, Bajaj NS, Arora G, Arora P. In-Hospital Management and Outcomes After ST-Segment-Elevation Myocardial Infarction in Medicaid Beneficiaries Compared With Privately Insured Individuals. *Circ Cardiovasc Qual Outcomes.* 2019;12:e004971.

25. Stretch R, Sauer CM, Yuh DD, Bonde P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. *J Am Coll Cardiol.* 2014;64:1407-15.

26. Strom JB, Zhao Y, Shen C, Chung M, Pinto DS, Popma JJ, Yeh RW. National trends, predictors of use, and in-hospital outcomes in mechanical circulatory support for cardiogenic shock. *EuroIntervention.* 2018;13:e2152-9.

27. Agarwal S, Sud K, Martin JM, Menon V. Trends in the Use of Mechanical Circulatory Support Devices in Patients Presenting With ST-Segment Elevation Myocardial Infarction. *JACC Cardiovasc Interv.* 2015;8:1772-4.

28. Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, Eitel I, Pöss J, Fuernau G, de Waha S. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. *Eur Heart J.* 2017;38:3523-31.

29. Vallabhajosyula S, Barsness GW, Vallabhajosyula S. Multidisciplinary teams for cardiogenic shock. *Aging (Albany NY).* 2019;11:4774-6.

30. Vallabhajosyula S, O'Horo JC, Antharam P, Ananthaneni S, Vallabhajosyula S, Stulak JM, Dunlay SM, Holmes DR Jr, Barsness GW. Venoarterial Extracorporeal Membrane Oxygenation With Concomitant Impella Versus Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock. *ASAIO J.* 2020;66:497-503.

31. Vallabhajosyula S, Patlolla SH, Sandhyavenu H, Vallabhajosyula S, Barsness GW, Dunlay SM, Greason KL, Holmes DR Jr, Eleid MF. Periprocedural Cardiopulmonary Bypass or Venoarterial Extracorporeal Membrane Oxygenation During Transcatheter Aortic Valve Replacement: A Systematic Review. *J Am Heart Assoc.* 2018;7:e009608.

32. Subramaniam AV, Barsness GW, Vallabhajosyula S, Vallabhajosyula S. Complications of Temporary Percutaneous Mechanical Circulatory Support for Cardiogenic Shock: An Appraisal of Contemporary Literature. *Cardiol Ther.* 2019;8:211-28.

33. Shaefi S, O'Gara B, Kociol RD, Joynt K, Mueller A, Nizamuddin J, Mahmood E, Talmor D, Shahul S. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. *J Am Heart Assoc.* 2015;4:e001462.

34. Lambert L, Blais C, Hamel D, Brown K, Rinfret S, Cartier R, Giguère M, Carroll C, Beauchamp C, Bogaty P. Evaluation of care and surveillance of cardiovascular disease: can we trust medico-administrative hospital data? *Can J Cardiol.* 2012;28:162-8.

Supplementary data

Supplementary Figure 1. Trends of MCS assistance for early PCI in AMI-CS classified by patient characteristics.

Supplementary Figure 2. Trends of MCS assistance for early PCI in AMI-CS classified by hospital characteristics.

Supplementary Table 1. Administrative codes used for identification of diagnoses and procedures.

Supplementary Table 2. Baseline, in-hospital course and management.

Supplementary Table 3. Multivariable regression for in-hospital mortality in AMI-CS.

Supplementary Table 4. Baseline characteristics of IABP-PCI versus pLVAD/ECMO-PCI.

The supplementary data are published online at: https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-19-00226

Supplementary data



Supplementary Figure 1. Trends of MCS assistance for early PCI in AMI-CS classified by patient characteristics.

Trends in the MCS-assisted PCI classified by (A) age, (B) sex, (C) race and (D) Charlson Comorbidity Index; all $p<0.001$ for trend.



Supplementary Figure 2. Trends of MCS assistance for early PCI in AMI-CS classified by hospital characteristics.

Trends in the MCS-assisted PCI classified by (A) region, (B) location and teaching status, and (C) bed size; all $p<0.001$ for trend.

Supplementary Table 1. Administrative codes used for identification of diagnoses and procedures.

Diagnosis/procedure	International classification of diseases 9.0 clinical modification codes
Coronary angiography	36.06, 37.22, 37.23, 88.53-88.56
Percutaneous coronary intervention	00.66, 36.01, 36.02, 36.05, 36.07, 88.57
Cardiac arrest	427.5
Right heart catheterisation	37.21, 37.23
Pulmonary artery catheterisation	204
Invasive mechanical ventilation	96.7, 96.70, 96.71, 96.72
Haemodialysis	39.95
Acute renal failure	584, 584.5, 584.6, 584.7, 584.8, 584.9
Acute respiratory failure	518.81, 518.85, 786.09, 799.1
Acute hepatic failure	570.x, 572.2, 573.3, 573.4
Acute metabolic failure	276.2
Acute neurologic failure	293, 293.0, 293.1, 293.8, 293.81-293.84, 293.89, 293.9, 348.1, 780.01, 780.09, 89.14, 348.3, 348.30, 348.31, 348.39

Supplementary Table 2. Baseline, in-hospital course and management.

Characteristic		MCS-assisted PCI (N=60,487)	PCI without MCS (N=49,965)	*p*-value
Weekend admission		28.1	28.0	0.27
Quartile of median household income for zip code	**0-25th**	26.5	26.8	<0.001
	26th-50th	26.0	26.8	
	51st-75th	25.0	25.1	
	76th-100th	22.6	21.3	
Hospital teaching status and location	**Rural**	5.2	5.4	<0.001
	Urban non-teaching	40.3	42.2	
	Urban teaching	54.5	52.4	
Hospital bed size	**Small**	6.3	7.6	<0.001
	Medium	21.7	23.3	
	Large	71.9	69.1	
Acute organ dysfunction	**Respiratory**	51.0	41.5	<0.001
	Renal	34.8	30.3	<0.001
	Hepatic	11.8	8.2	<0.001
	Haematologic	12.8	7.3	<0.001
	Metabolic	20.3	16.4	<0.001
	Neurologic	17.9	15.8	<0.001
Cardiac arrest		25.6	20.7	<0.001
Right heart/pulmonary artery catheterisation		22.4	13.2	<0.001
Intubated at admission (day 0)		39.5	27.5	<0.001
Haemodialysis		3.0	2.8	0.10

Supplementary Table 3. Multivariable regression for in-hospital mortality in AMI-CS.

Total cohort (N=110,452)		Odds ratio	95% confidence interval		*p*-value
			Lower limit	Upper limit	
MCS-assisted PCI		1.23	1.19	1.27	<0.001
Age groups, years	**19-49**	Reference category			
	50-59	1.12	1.04	1.19	0.001
	60-69	1.71	1.59	1.83	<0.001
	70-79	2.85	2.62	3.10	<0.001
	≥80	4.92	4.51	5.37	<0.001
Female sex		1.15	1.12	1.19	<0.001
Race	**White**	Reference category			
	Black	0.99	0.93	1.05	0.72
	Hispanic	1.13	1.06	1.20	<0.001
	Asian	0.88	0.80	0.96	0.005
	Native American	1.38	1.12	1.70	0.003
	Others	1.02	0.94	1.10	0.67
Year of admission	**2005**	Reference category			
	2006	1.09	1.00	1.19	0.05
	2007	0.97	0.89	1.05	0.46
	2008	0.71	0.66	0.78	<0.001
	2009	0.58	0.53	0.63	<0.001
	2010	0.61	0.57	0.67	<0.001
	2011	0.63	0.58	0.68	<0.001
	2012	0.62	0.57	0.67	<0.001
	2013	0.61	0.57	0.66	<0.001
	2014	0.63	0.59	0.68	<0.001
Primary payer	**Medicare**	Reference category			
	Medicaid	0.86	0.80	0.92	<0.001
	Private	0.72	0.68	0.75	<0.001
	Uninsured	1.32	1.24	1.42	<0.001
	No charge	0.88	0.71	1.08	0.22
	Others	0.80	0.72	0.89	<0.001

Quartile of median household income for zip code	**0-25th**	Reference category			
	26th-50th	0.89	0.85	0.93	<0.001
	51st-75th	0.86	0.83	0.90	<0.001
	76th-100th	0.83	0.80	0.87	<0.001
Inter-hospital transfer		1.03	0.99	1.07	0.13
Hospital teaching status and location	**Rural**	Reference category			
	Urban non-teaching	0.89	0.83	0.96	0.002
	Urban teaching	0.97	0.90	1.04	0.40
Hospital bed size	**Small**	Reference category			
	Medium	1.03	0.96	1.10	0.39
	Large	1.07	1.00	1.14	0.04
Hospital region	**Northeast**	Reference category			
	Midwest	1.01	0.95	1.06	0.84
	South	1.15	1.10	1.20	<0.001
	West	1.04	0.98	1.09	0.18
Charlson Comorbidity Index	**0-3**	Reference category			
	4-6	0.73	0.70	0.77	<0.001
	≥7	0.62	0.58	0.66	<0.001
Acute organ dysfunction	**Respiratory**	1.28	1.24	1.33	<0.001
	Renal	1.48	1.43	1.54	<0.001
	Hepatic	1.33	1.27	1.40	<0.001
	Haematological	0.82	0.78	0.86	<0.001
	Metabolic	2.09	2.01	2.17	<0.001
	Neurological	1.68	1.61	1.75	<0.001
Cardiac arrest		2.23	2.15	2.31	<0.001
Right heart/pulmonary artery catheterisation		1.09	1.05	1.14	<0.001
Intubated at admission (day 0)		1.58	1.52	1.63	<0.001
Haemodialysis		1.70	1.56	1.85	<0.001

Supplementary Table 4. Baseline characteristics of IABP-PCI versus pLVAD/ECMO-PCI.

Characteristic		IABP-assisted PCI (N=57,337)	pLVAD/ECMO-assisted PCI (N=3,150)	*p*-value
AMI type	**STEMI**	87.4	85.7	0.004
	NSTEMI	12.6	14.3	
Age, years		64.9±12.7	62.0±11.9	<0.001
Female sex		31.4	23.3	<0.001
Race	**White**	68.2	62.4	<0.001
	Black	5.9	9.6	
	Hispanic	8.1	8.2	
	Asian	3.0	3.9	
	Native American	0.5	0.6	
	Others	4.1	5.9	
	Missing	10.2	9.4	
Weekend admission		28.3	24.5	<0.001
Primary payer	**Medicare**	48.3	40.7	<0.001
	Medicaid	8.3	10.0	
	Private	31.5	38.3	
	Uninsured	8.1	7.2	
	No charge	0.6	0.2	
	Others	3.2	3.6	
Quartile of median household income for zip code	**0-25th**	26.3	28.9	<0.001
	26th-50th	25.9	26.8	
	51st-75th	25.2	21.6	
	76th-100th	22.5	22.7	
Charlson Comorbidity Index	**0-3**	36.4	39.5	0.002
	4-6	49.7	47.0	
	≥7	13.9	13.5	
Cardiac arrest		24.8	39.9	<0.001
Intubated on admission (day 0)		39.3	42.7	<0.001